Announcement • Jun 03
Lupin Limited and Natco Pharma Limited Receive Approval from U.S. FDA for Eribulin Mesylate Injection Lupin Limited and its alliance partner Natco Pharma Limited announced the approval from the United States Food and Drug Administration for Natco's Abbreviated New Drug Application for Eribulin Mesylate Injection, 1 mg/2 mL (0.5 mg/mL) Single-Dose Vials. Eribulin Mesylate Injection, 1 mg/2 mL (0.5 mg/mL) Single-Dose Vials is the bioequivalent to the reference listed drug Halaven Injection of Eisai Inc. Eribulin Mesylate Injection is indicated for the treatment of adults with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease and unresectable or metastatic liposarcoma who have received a prior anthracycline-containing regimen. Eribulin Mesylate Injection (reference listed drug Halaven) had estimated annual sales of USD 43.7 million in the U.S. (IQVIA MAT April 2026). Price Target Changed • Jun 01
Price target increased by 7.2% to ₹1,007 Up from ₹940, the current price target is an average from 9 analysts. New target price is 7.9% above last closing price of ₹933. Stock is up 6.2% over the past year. The company is forecast to post earnings per share of ₹41.50 for next year compared to ₹79.20 last year. Reported Earnings • May 30
Full year 2026 earnings: EPS exceeds analyst expectations Full year 2026 results: EPS: ₹79.20 (down from ₹105 in FY 2025). Revenue: ₹43.8b (down 1.3% from FY 2025). Net income: ₹14.2b (down 25% from FY 2025). Profit margin: 32% (down from 43% in FY 2025). The decrease in margin was primarily driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 9.5%. Revenue is expected to decline by 9.7% p.a. on average during the next 2 years, while revenues in the Pharmaceuticals industry in India are expected to grow by 11%. Over the last 3 years on average, earnings per share has increased by 19% per year whereas the company’s share price has increased by 17% per year. Announcement • May 30
Natco Pharma Limited Provides Earnings Guidance for 2027 NATCO Pharma Limited provided earnings guidance for 2027. For the period, the company expects to do about INR 34,000 million to INR 35,000 million of revenue. Announcement • May 18
NATCO Pharma Limited to Report Q4, 2026 Results on May 29, 2026 NATCO Pharma Limited announced that they will report Q4, 2026 results on May 29, 2026 Declared Dividend • Feb 14
Dividend of ₹1.50 announced Dividend of ₹1.50 is the same as last year. Ex-date: 18th February 2026 Payment date: 14th March 2026 Dividend yield will be 0.6%, which is lower than the industry average of 0.8%. Sustainability & Growth Dividend is well covered by both earnings (6% earnings payout ratio) and cash flows (7% cash payout ratio). The dividend has increased by an average of 17% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to decline by 57% over the next 2 years. However, it would need to fall by 94% to increase the payout ratio to a potentially unsustainable range. Reported Earnings • Feb 13
Third quarter 2026 earnings: EPS and revenues miss analyst expectations Third quarter 2026 results: EPS: ₹8.46 (up from ₹7.43 in 3Q 2025). Revenue: ₹7.05b (up 49% from 3Q 2025). Net income: ₹1.52b (up 14% from 3Q 2025). Profit margin: 22% (down from 28% in 3Q 2025). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 8.4%. Earnings per share (EPS) also missed analyst estimates by 2.4%. Revenue is expected to decline by 16% p.a. on average during the next 3 years, while revenues in the Pharmaceuticals industry in India are expected to grow by 10%. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has only increased by 15% per year, which means it is significantly lagging earnings growth. Announcement • Jan 28
NATCO Pharma Limited to Report Q3, 2026 Results on Feb 12, 2026 NATCO Pharma Limited announced that they will report Q3, 2026 results on Feb 12, 2026 Declared Dividend • Nov 17
Dividend of ₹1.50 announced Dividend of ₹1.50 is the same as last year. Ex-date: 20th November 2025 Payment date: 14th December 2025 Dividend yield will be 0.6%, which is lower than the industry average of 0.8%. Sustainability & Growth Dividend is well covered by both earnings (2% earnings payout ratio) and cash flows (7% cash payout ratio). The dividend has increased by an average of 17% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to decline by 74% over the next 3 years. However, it would need to fall by 98% to increase the payout ratio to a potentially unsustainable range. Reported Earnings • Nov 16
Second quarter 2026 earnings: EPS and revenues exceed analyst expectations Second quarter 2026 results: EPS: ₹28.94 (down from ₹37.81 in 2Q 2025). Revenue: ₹14.6b (up 6.7% from 2Q 2025). Net income: ₹5.18b (down 24% from 2Q 2025). Profit margin: 35% (down from 49% in 2Q 2025). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 13%. Earnings per share (EPS) also surpassed analyst estimates by 18%. Revenue is expected to decline by 18% p.a. on average during the next 3 years, while revenues in the Pharmaceuticals industry in India are expected to grow by 11%. Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has only increased by 12% per year, which means it is significantly lagging earnings growth. Announcement • Nov 08
NATCO Pharma Limited to Report Q2, 2026 Results on Nov 14, 2025 NATCO Pharma Limited announced that they will report Q2, 2026 results on Nov 14, 2025 Announcement • Sep 01
NATCO Pharma Limited, Annual General Meeting, Sep 25, 2025 NATCO Pharma Limited, Annual General Meeting, Sep 25, 2025, at 11:00 Indian Standard Time. Reported Earnings • Aug 13
First quarter 2026 earnings: EPS and revenues miss analyst expectations First quarter 2026 results: EPS: ₹26.84 (down from ₹37.32 in 1Q 2025). Revenue: ₹13.9b (up 2.1% from 1Q 2025). Net income: ₹4.81b (down 28% from 1Q 2025). Profit margin: 35% (down from 49% in 1Q 2025). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 11%. Earnings per share (EPS) also missed analyst estimates by 25%. Revenue is expected to decline by 17% p.a. on average during the next 3 years, while revenues in the Pharmaceuticals industry in India are expected to grow by 10%. Over the last 3 years on average, earnings per share has increased by 49% per year but the company’s share price has only increased by 12% per year, which means it is significantly lagging earnings growth. Announcement • Aug 04
NATCO Pharma Limited to Report Q1, 2026 Results on Aug 12, 2025 NATCO Pharma Limited announced that they will report Q1, 2026 results on Aug 12, 2025 Announcement • Jul 23
NATCO Pharma Limited (NSEI:NATCOPHARM) entered into an implementation agreement to acquire additional 34.3% stake in Adcock Ingram Holdings Limited (JSE:AIP) for ZAR 3.8 billion. NATCO Pharma Limited (NSEI:NATCOPHARM) entered into an implementation agreement to acquire additional 34.3% stake in Adcock Ingram Holdings Limited (JSE:AIP) for ZAR 3.8 billion on July 23, 2025. A cash consideration valued at ZAR 75 per share will be paid by NATCO Pharma Limited. In the event that the Offer is implemented, it would result in the delisting of all the Ordinary Shares from the Main Board of the securities exchange operated by the JSE, and on a fully diluted basis, Bidvest will remain the controlling shareholder (owning approximately 64.25% of the Ordinary Shares) and Natco Pharma becoming a co-shareholder (and owning approximately 35.75% of the Ordinary Shares) in the delisted Adcock Ingram. Post-transaction, NATCO will consolidate 35.75% of Adcock Ingram's net profits in NATCO’s financial results in accordance with its shareholding. Investec Bank Limited on behalf of the Offeror has provided an irrevocable bank guarantee to the TRP and for the benefit of the Adcock Ingram Shareholders, in which Investec has agreed to pay up to a maximum guaranteed amount of ZAR4 billion in the event that the Offeror fails to discharge its obligation to make payment of all monies due under the Offer and in connection with the treatment of the relevant share incentive schemes by the due date for payment.
The transaction is subject to approval by regulatory board / committee. e Board of Directors of NATCO have also approved the transaction. Business operations will remain uninterrupted, with no changes to existing partnerships, joint ventures, or supplier relationships. Adcock Ingram will be delisted from the JSE if the transaction proceeds. Upon implementation of the Scheme, the Ordinary Shares will be delisted from the JSE. The expected completion of the transaction is on or before the end of December 31, 2025. BDO Corporate Finance Proprietary Limited act as fairness opinion provider, Goldman Sachs International as financial advisor, Edward Nathan Sonnenbergs Inc. as legal advisor for Adcock Ingram Holdings Limited. Investec Bank Limited as financial advisor, Bowmans as legal advisor for NATCO Pharma Limited. Price Target Changed • Jun 09
Price target decreased by 8.2% to ₹962 Down from ₹1,047, the current price target is an average from 11 analysts. New target price is 11% above last closing price of ₹863. Stock is down 21% over the past year. The company is forecast to post earnings per share of ₹69.80 for next year compared to ₹105 last year. Reported Earnings • May 29
Full year 2025 earnings: EPS and revenues miss analyst expectations Full year 2025 results: EPS: ₹105 (up from ₹77.35 in FY 2024). Revenue: ₹47.8b (up 20% from FY 2024). Net income: ₹18.9b (up 36% from FY 2024). Profit margin: 39% (up from 35% in FY 2024). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 3.2%. Earnings per share (EPS) also missed analyst estimates by 3.2%. Revenue is expected to decline by 17% p.a. on average during the next 2 years, while revenues in the Pharmaceuticals industry in India are expected to grow by 10%. Over the last 3 years on average, earnings per share has increased by 60% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth. Announcement • May 13
NATCO Pharma Limited to Report Q4, 2025 Results on May 28, 2025 NATCO Pharma Limited announced that they will report Q4, 2025 results on May 28, 2025 New Risk • Apr 30
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 30% per year for the foreseeable future. Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (8.5% average weekly change). Announcement • Apr 08
NATCO Pharma Limited Provides Legal Update Regarding Risdiplam Launch in India NATCO Pharma Limited updates on the legal proceedings on Risdiplam launch in India. The Company has received numerous enquiries from investors and patients about the launch, availability and pricing of generic version of Risdiplam in the Indian market. The Company wishes to clarify that the Ld. Single Court had through order dated 24.03.2025 denied Roche's plea for an injunction against the Company for the drug. However, Roche has appealed the decision before the Appellate Bench of the Delhi High Court who has currently directed to maintain the status quo. Due to pendency of the proceedings before the court, the Company does not wish to comment on the status of the proceedings. However, it has been the stand of the Company that it intends to launch the drug only after and subject to successful clarity from the Appellate Bench of The Delhi High Court which is expected shortly. Subject to the foregoing, the Company has decided to price the product at INR 15,900 MRP consistent with the Company's stand before the court. The Company also intends to offer discount to certain deserving patients through its patient access programme. Announcement • Apr 03
NATCO Pharma Limited Announces Superannuation of Ramesh Dandala, Executive Vice President - Technology Transfer, Intellectual Property Rights & Regulatory Affairs NATCO Pharma Limited informed that in accordance with the provisions of Regulation 30 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Dr. Ramesh Dandala, Executive Vice President - Technology Transfer, Intellectual Property Rights & Regulatory Affairs (API) of the Company has superannuated, with effect from the closure of business hours on 3rd April, 2025. Announcement • Mar 03
NATCO Pharma Limited Appoints Bhimrao Dattu Jadhav as Senior Vice President Operations (Formulations) NATCO Pharma Limited announced appointment of Mr. Bhimrao Dattu Jadhav as Senior Vice President Operations (Formulations).
Mr. Bhimrao Dattu Jadhav has completed his B. Pharmacy and is having 30+ years of rich experience in Operation Management in Pharmaceutical Industry. He was associated with INTAS Pharmaceutical Laboratories Ltd. as Senior Vice President operations (Site Head) since 2018. Prior to that, he was working with Dr. Reddy's Labs as Vice President Operations since 2006. Date of Appointment & Term of Appointment: 3 March, 2025 & Terms of appointment are as per the Company's Policy. Valuation Update With 7 Day Price Move • Feb 19
Investor sentiment deteriorates as stock falls 33% After last week's 33% share price decline to ₹812, the stock trades at a forward P/E ratio of 8x. Average forward P/E is 28x in the Pharmaceuticals industry in India. Total returns to shareholders of 1.2% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₹418 per share. New Risk • Feb 14
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 24% per year for the foreseeable future. Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (7.9% average weekly change). Price Target Changed • Feb 14
Price target decreased by 15% to ₹1,152 Down from ₹1,349, the current price target is an average from 12 analysts. New target price is 30% above last closing price of ₹884. Stock is down 14% over the past year. The company is forecast to post earnings per share of ₹109 for next year compared to ₹77.34 last year. Reported Earnings • Feb 13
Third quarter 2025 earnings: EPS and revenues miss analyst expectations Third quarter 2025 results: EPS: ₹7.43 (down from ₹11.88 in 3Q 2024). Revenue: ₹6.51b (down 14% from 3Q 2024). Net income: ₹1.33b (down 38% from 3Q 2024). Profit margin: 20% (down from 28% in 3Q 2024). The decrease in margin was driven by lower revenue. Revenue missed analyst estimates by 45%. Earnings per share (EPS) also missed analyst estimates by 44%. Revenue is expected to decline by 3.7% p.a. on average during the next 3 years, while revenues in the Pharmaceuticals industry in India are expected to grow by 11%. Over the last 3 years on average, earnings per share has increased by 66% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth. Announcement • Feb 12
NATCO Pharma Limited Announces Resignation of Pavan Ganapati Bhat as Director & Executive Vice President (Technical Operations) NATCO Pharma Limited announced that the Board at their meeting held on 12th February, 2025 took note of the resignation tendered by Dr. Pavan Ganapati Bhat (DIN: 09691260), Director & Executive Vice President (Technical Operations) of the Company due to new career opportunity outside the Company, with effect from the close of the business hours on 12th February, 2025. Announcement • Feb 11
Lupin Limited and Natco Pharma Limited Receive Approval from U.S. FDA for Bosentan Tablets for Oral Suspension Lupin Limited and its alliance partner Natco Pharma Limited announced that they have received an approval from the United States Food and Drug Administration (U.S. FDA) for Natco's Abbreviated New Drug Application (ANDA) for Bosentan Tablets for Oral Suspension, 32 mg, to market a generic equivalent of Tracleer®? Tablets for Oral Suspension of Actelion Pharmaceuticals US Inc. Natco is the exclusive first-to-file for this product and is eligible for 180 days exclusivity. Bosentan Tablets for oral Suspension are indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) in pediatric patients aged 3 years and older with idiopathic or congenital PAH to improve pulmonary vascular resistance (PVR), which is expected to result in an improvement in exercise ability. BosentanTablets for Oral Suspension (RLD Tracleer®?) had estimated annual sales of USD 11 million in the U.S. (IQVIA MAT December 2024). Announcement • Feb 10
NATCO Pharma Limited Announces Final Approval of Its ANDA for Bosentan Tablets for Oral Suspension (TFOS), 32Mg NATCO Pharma Limited announced final approval of its ANDA for Bosentan tablets for oral suspension (TFOS), 32mg, a generic version of Tracleer®? by Actelion Pharmaceuticals US Inc. NATCO's marketing partner for the ANDA, Lupin Pharmaceuticals Inc. (Lupin) will market the product in the U.S. NATCO believes it has sole First-to-File status for the product and is eligible for a 180-day exclusivity at the time of launch. Launch details are bound by confidentiality. Bosentan TFOS is indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) in pediatric patients aged 3 years and older with idiopathic or congenital PAH to improve pulmonary vascular resistance (PVR), which is expected to result in an improvement in exercise ability. Bosentan tablets for oral suspended (TFOS), 32mg had estimated sales of USD 11 million in the U.S. for 12 months ending Sep'24 as per industry sales data. Buy Or Sell Opportunity • Feb 04
Now 20% overvalued Over the last 90 days, the stock has fallen 15% to ₹1,235. The fair value is estimated to be ₹1,026, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 35% over the last 3 years. Earnings per share has grown by 70%. Revenue is forecast to grow by 1.7% in 2 years. Earnings are forecast to decline by 20% in the next 2 years. Announcement • Jan 30
NATCO Pharma Limited to Report Q3, 2025 Results on Feb 12, 2025 NATCO Pharma Limited announced that they will report Q3, 2025 results at 9:08 AM, Indian Standard Time on Feb 12, 2025 Recent Insider Transactions • Jan 04
Insider recently sold ₹3.5m worth of stock On the 27th of December, Tummala Rao sold around 3k shares on-market at roughly ₹1,380 per share. This transaction amounted to 3.9% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth ₹7.3m. Insiders have been net sellers, collectively disposing of ₹83m more than they bought in the last 12 months. Declared Dividend • Nov 14
Dividend of ₹1.50 announced Shareholders will receive a dividend of ₹1.50. Ex-date: 25th November 2024 Payment date: 12th December 2024 Dividend yield will be 0.4%, which is lower than the industry average of 0.8%. Sustainability & Growth Dividend is well covered by both earnings (1% earnings payout ratio) and cash flows (8% cash payout ratio). The dividend has increased by an average of 19% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to decline by 47% over the next 3 years. However, it would need to fall by 99% to increase the payout ratio to a potentially unsustainable range. Reported Earnings • Nov 13
Second quarter 2025 earnings: EPS and revenues exceed analyst expectations Second quarter 2025 results: EPS: ₹37.81 (up from ₹20.60 in 2Q 2024). Revenue: ₹14.3b (up 39% from 2Q 2024). Net income: ₹6.77b (up 84% from 2Q 2024). Profit margin: 47% (up from 36% in 2Q 2024). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 4.1%. Earnings per share (EPS) also surpassed analyst estimates by 20%. Revenue is expected to decline by 1.1% p.a. on average during the next 3 years, while revenues in the Pharmaceuticals industry in India are expected to grow by 11%. Over the last 3 years on average, earnings per share has increased by 70% per year but the company’s share price has only increased by 19% per year, which means it is significantly lagging earnings growth. Announcement • Oct 29
NATCO Pharma Limited to Report First Half, 2025 Results on Nov 12, 2024 NATCO Pharma Limited announced that they will report first half, 2025 results on Nov 12, 2024 Recent Insider Transactions • Sep 04
Insider recently sold ₹30m worth of stock On the 30th of August, Mente Rao sold around 20k shares on-market at roughly ₹1,514 per share. This transaction amounted to 36% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of ₹161m more than they bought in the last 12 months. Board Change • Sep 01
High number of new directors There are 6 new directors who have joined the board in the last 3 years. Independent Director Lakshminarayana Bolisetty was the last director to join the board, commencing their role in 2024. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Announcement • Aug 29
Natco Pharma Limited Submits Abbreviated New Drug Application Containing A Paragraph IV Certification with the U.S. Food and Drug Administration Natco Pharma Limited announced its submission of an Abbreviated New Drug Application (ANDA) containing a paragraph IV certification with the U.S. Food and Drug Administration (FDA) for the generic version of TABRECTA (Capmatinib hydrochloride) Eq 150mg base and Eq 200 mg base tablets. TABRECTA ® is the brand of Novartis. Natco believes it is the first company to have filed a substantially-complete ANDA containing a paragraph IV certification for this product and expects to be eligible for 180 days of sole marketing exclusivity at the time of potential launch of the product under certain circumstances. TABRECTA has recorded sales of USD 126 million in the US market for the year 2023. Capmatinib hydrochloride is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with a specific type of mutation. Board Change • Aug 27
Less than half of directors are independent Following the recent departure of a director, there are only 4 independent directors on the board. The company's board is composed of: 4 independent directors. 5 non-independent directors. Independent Director Agnihotra Dakshina Chavali was the last independent director to join the board, commencing their role in 2024. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Price Target Changed • Aug 15
Price target increased by 14% to ₹1,209 Up from ₹1,064, the current price target is an average from 12 analysts. New target price is 17% below last closing price of ₹1,458. Stock is up 70% over the past year. The company is forecast to post earnings per share of ₹110 for next year compared to ₹77.34 last year. Announcement • Aug 14
NATCO Pharma Limited Declares Interim Dividend for the Financial Year 2024-25, Payable from August 30, 2024 NATCO Pharma Limited at its board meeting held on August 12, 2024 declared interim dividend of INR 3.00 per share for the financial year 2024-25. The date for taking on record of its shareholders eligible for the purpose of payment of interim dividend i.e., record date is fixed as the 23rd day of August, 2024. The payment of said interim dividend will start from 30th August, 2024. Declared Dividend • Aug 14
Dividend of ₹3.00 announced Shareholders will receive a dividend of ₹3.00. Ex-date: 23rd August 2024 Payment date: 11th September 2024 Dividend yield will be 0.4%, which is lower than the industry average of 0.8%. Sustainability & Growth Dividend is well covered by both earnings (6% earnings payout ratio) and cash flows (20% cash payout ratio). The dividend has increased by an average of 25% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to decline by 16% over the next 3 years. However, it would need to fall by 93% to increase the payout ratio to a potentially unsustainable range. Reported Earnings • Aug 13
First quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind First quarter 2025 results: EPS: ₹37.32 (up from ₹23.26 in 1Q 2024). Revenue: ₹14.1b (up 24% from 1Q 2024). Net income: ₹6.69b (up 59% from 1Q 2024). Profit margin: 47% (up from 37% in 1Q 2024). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 2.1%. Earnings per share (EPS) missed analyst estimates by 11%. Revenue is forecast to grow 2.1% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 66% per year but the company’s share price has only increased by 15% per year, which means it is significantly lagging earnings growth. Announcement • Aug 13
NATCO Pharma Limited Announces Term Completion of Directors NATCO Pharma Limited at its Annual General Meeting held on August 12, 2024, took note of Dr. T.V. Rao, Independent Director completing his second term of 5 years as an Independent Director of the Company with effect from August 24, 2024 and Dr. Leela Digumarti, Independent Director completing her second term of 5 years as an Independent Director of the Company with effect from September 21, 2024. Announcement • Aug 12
NATCO Pharma Limited, Annual General Meeting, Sep 30, 2024 NATCO Pharma Limited, Annual General Meeting, Sep 30, 2024, at 11:00 Indian Standard Time. Announcement • Jul 27
NATCO Pharma Limited Announces Resignation of Sanivarapu Ravi Prakash Reddy as Senior Vice President - Operations NATCO Pharma Limited announced that Mr. Sanivarapu Ravi Prakash Reddy, Senior Vice President - Operations, Pharma Division, Kothur, Rangareddy District, Telangana has resigned and relieved with effect from 25th July, 2024. Announcement • Jul 26
NATCO Pharma Limited to Report Q1, 2025 Results on Aug 12, 2024 NATCO Pharma Limited announced that they will report Q1, 2025 results at 12:08 PM, Indian Standard Time on Aug 12, 2024 Recent Insider Transactions • Jun 27
Board Member recently sold ₹6.0m worth of stock On the 24th of June, Potluri Prasad sold around 5k shares on-market at roughly ₹1,200 per share. This transaction amounted to 11% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of ₹137m more than they bought in the last 12 months. Valuation Update With 7 Day Price Move • Jun 11
Investor sentiment improves as stock rises 21% After last week's 21% share price gain to ₹1,173, the stock trades at a forward P/E ratio of 12x. Average forward P/E is 32x in the Pharmaceuticals industry in India. Total returns to shareholders of 8.7% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₹579 per share. Price Target Changed • May 31
Price target increased by 9.1% to ₹1,064 Up from ₹975, the current price target is an average from 12 analysts. New target price is 6.6% above last closing price of ₹998. Stock is up 59% over the past year. The company is forecast to post earnings per share of ₹98.35 for next year compared to ₹77.34 last year. Reported Earnings • May 28
Full year 2024 earnings: EPS and revenues exceed analyst expectations Full year 2024 results: EPS: ₹77.34 (up from ₹39.18 in FY 2023). Revenue: ₹41.3b (up 52% from FY 2023). Net income: ₹13.9b (up 94% from FY 2023). Profit margin: 34% (up from 26% in FY 2023). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 2.0%. Earnings per share (EPS) also surpassed analyst estimates by 5.6%. Revenue is forecast to grow 9.2% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 58% per year but the company’s share price has remained flat, which means it is significantly lagging earnings. Announcement • May 11
NATCO Pharma Limited to Report Q4, 2024 Results on May 27, 2024 NATCO Pharma Limited announced that they will report Q4, 2024 results on May 27, 2024 Buy Or Sell Opportunity • Mar 28
Now 22% undervalued Over the last 90 days, the stock has risen 17% to ₹952. The fair value is estimated to be ₹1,214, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 25% over the last 3 years. Earnings per share has grown by 47%. Revenue is forecast to grow by 25% in 2 years. Earnings are forecast to grow by 34% in the next 2 years. Buy Or Sell Opportunity • Mar 12
Now 20% undervalued Over the last 90 days, the stock has risen 27% to ₹966. The fair value is estimated to be ₹1,212, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 25% over the last 3 years. Earnings per share has grown by 47%. Revenue is forecast to grow by 25% in 2 years. Earnings are forecast to grow by 34% in the next 2 years. Valuation Update With 7 Day Price Move • Feb 21
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₹1,025, the stock trades at a forward P/E ratio of 12x. Average forward P/E is 31x in the Pharmaceuticals industry in India. Total returns to shareholders of 30% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₹1,215 per share. Upcoming Dividend • Feb 19
Upcoming dividend of ₹1.25 per share Eligible shareholders must have bought the stock before 26 February 2024. Payment date: 04 March 2024. Payout ratio is a comfortable 13% and this is well supported by cash flows. Trailing yield: 0.9%. Lower than top quartile of Indian dividend payers (1.2%). Higher than average of industry peers (0.7%). Price Target Changed • Feb 16
Price target increased by 8.9% to ₹895 Up from ₹822, the current price target is an average from 10 analysts. New target price is 13% below last closing price of ₹1,027. Stock is up 92% over the past year. The company is forecast to post earnings per share of ₹73.71 for next year compared to ₹39.18 last year. Reported Earnings • Feb 15
Third quarter 2024 earnings: EPS and revenues exceed analyst expectations Third quarter 2024 results: EPS: ₹11.88 (up from ₹3.41 in 3Q 2023). Revenue: ₹7.96b (up 62% from 3Q 2023). Net income: ₹2.13b (up 241% from 3Q 2023). Profit margin: 27% (up from 13% in 3Q 2023). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 32%. Earnings per share (EPS) also surpassed analyst estimates. Revenue is forecast to grow 9.7% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 47% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth. Announcement • Feb 14
Corporate Action-Board Approves Third Interim Dividend for the Financial Year 2023-24, Payable on 4 March 2024 The Board of Directors of NATCO Pharma Limited at their meeting held on February 14, 2024, have Declared third interim dividend of INR 1.25/- (Rupees one and paise twenty five only) (62.50%) each per equity share of INR 2/- (Rupees two only) each for the financial year 2023-24. The date for taking on record of its shareholders eligible for the purpose of payment of third interim dividend i.e., record date is fixed as the 26 February 2024. The payment of said interim dividend will start from 4 March 2024. Announcement • Feb 03
NATCO Pharma Limited to Report Q3, 2024 Results on Feb 14, 2024 NATCO Pharma Limited announced that they will report Q3, 2024 results on Feb 14, 2024 Recent Insider Transactions • Jan 02
Board Member recently sold ₹8.0m worth of stock On the 28th of December, Donthineni Rao sold around 10k shares on-market at roughly ₹800 per share. This transaction amounted to 16% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of ₹129m more than they bought in the last 12 months. Recent Insider Transactions • Dec 27
Insider recently sold ₹1.2m worth of stock On the 22nd of December, A. Lakshminarayana sold around 2k shares on-market at roughly ₹800 per share. This transaction amounted to 12% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth ₹7.9m. Insiders have been net sellers, collectively disposing of ₹121m more than they bought in the last 12 months. Recent Insider Transactions • Dec 27
Insider recently sold ₹1.2m worth of stock On the 22nd of December, A. Lakshminarayana sold around 2k shares on-market at roughly ₹800 per share. This transaction amounted to 12% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth ₹7.9m. Insiders have been net sellers, collectively disposing of ₹121m more than they bought in the last 12 months. Recent Insider Transactions • Dec 13
Board Member recently sold ₹7.9m worth of stock On the 4th of December, Potluri Prasad sold around 10k shares on-market at roughly ₹793 per share. This transaction amounted to 18% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of ₹110m more than they bought in the last 12 months. Recent Insider Transactions • Nov 24
Insider recently sold ₹1.6m worth of stock On the 20th of November, A. Lakshminarayana sold around 2k shares on-market at roughly ₹784 per share. This transaction amounted to 14% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth ₹54m. Insiders have been net sellers, collectively disposing of ₹101m more than they bought in the last 12 months. Announcement • Nov 15
NATCO Pharma Limited Declares Second Interim Dividend for the Financial Year 2023-24, Payable on 1 December, 2023 The Board of Directors of NATCO Pharma Limited at their meeting held have Declared second interim dividend of INR 1.25/- (Rupees one and paise twenty five only) (62.50%) each per equity share of INR 2/- (Rupees two only) each for the financial year 2023-24. The date for taking on record of its shareholders eligible for the purpose of payment of second interim dividend i.e., record date is fixed as the 24th day of November, 2023. The payment of said interim dividend will start from 1st December, 2023. Reported Earnings • Nov 15
Second quarter 2024 earnings: EPS and revenues miss analyst expectations Second quarter 2024 results: EPS: ₹20.60 (up from ₹3.11 in 2Q 2023). Revenue: ₹10.6b (up 146% from 2Q 2023). Net income: ₹3.69b (up ₹3.12b from 2Q 2023). Profit margin: 35% (up from 13% in 2Q 2023). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 4.4%. Earnings per share (EPS) also missed analyst estimates by 3.9%. Revenue is forecast to grow 8.9% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings. Announcement • Nov 04
NATCO Pharma Limited to Report Q2, 2024 Results on Nov 14, 2023 NATCO Pharma Limited announced that they will report Q2, 2024 results on Nov 14, 2023 Announcement • Sep 05
NATCO Pharma Limited, Annual General Meeting, Sep 29, 2023 NATCO Pharma Limited, Annual General Meeting, Sep 29, 2023, at 10:30 Indian Standard Time. Agenda: To receive, consider and adopt the Audited Financial Statements, both on Standalone and Consolidated basis of the Company for the Financial Year ended March 31, 2023, together with the reports of Board of Directors, and the Auditors and other reports thereon; to confirm three interim dividends aggregating to E 5.50 Rs per share paid on equity shares during the Financial Year 2022-23 as dividend for the FY 2022-23; to consider Re-appointment of Sri P.S.R.K Prasad as a Director liable to retire by rotation; and to consider other business matters. Upcoming Dividend • Aug 15
Upcoming dividend of ₹7.00 per share at 0.7% yield Eligible shareholders must have bought the stock before 22 August 2023. Payment date: 08 September 2023. Payout ratio is a comfortable 20% and this is well supported by cash flows. Trailing yield: 0.7%. Lower than top quartile of Indian dividend payers (1.4%). Lower than average of industry peers (0.9%). Price Target Changed • Aug 11
Price target increased by 9.6% to ₹734 Up from ₹670, the current price target is an average from 13 analysts. New target price is 13% below last closing price of ₹848. Stock is up 31% over the past year. The company is forecast to post earnings per share of ₹21.50 for next year compared to ₹39.18 last year. Announcement • Aug 10
NATCO Pharma Limited Declares Interim Dividend for the Financial Year 2023-24 NATCO Pharma Limited at its board meeting held on August 09, 2023, declared interim dividend of INR 7/(350 %) per equity share of INR 2/- each for the financial year 2023-24. The date for taking on record of its shareholders eligible for the purpose of payment of interim dividend i.e., record date is fixed as the 22nd day of August 2023. The payment of said interim dividend will start from 30th August 2023. Reported Earnings • Aug 10
First quarter 2024 earnings: EPS exceeds analyst expectations First quarter 2024 results: EPS: ₹23.26 (up from ₹17.55 in 1Q 2023). Revenue: ₹11.6b (up 31% from 1Q 2023). Net income: ₹4.20b (up 31% from 1Q 2023). Profit margin: 36% (in line with 1Q 2023). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 22%. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 9.9% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth. Announcement • Aug 01
NATCO Pharma Limited to Report Q1, 2024 Results on Aug 09, 2023 NATCO Pharma Limited announced that they will report Q1, 2024 results on Aug 09, 2023 Announcement • May 30
NATCO Pharma Limited (NSEI:NATCOPHARM) agreed to acquire Zista Pharma Limited for $3 million. NATCO Pharma Limited (NSEI:NATCOPHARM) agreed to acquire Zista Pharma Limited for $3 million on May 29, 2023. NATCO Pharma board approved the deal. The transaction is subject to ODI under FEMA regulations. The transaction is expected to complete on December 31, 2023. Reported Earnings • May 30
Full year 2023 earnings: Revenues and EPS in line with analyst expectations Full year 2023 results: EPS: ₹39.18 (up from ₹9.32 in FY 2022). Revenue: ₹28.1b (up 45% from FY 2022). Net income: ₹7.15b (up 321% from FY 2022). Profit margin: 25% (up from 8.7% in FY 2022). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) were also in line with analyst expectations. Revenue is forecast to grow 13% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has remained flat whereas the company’s share price has increased by 1% per year. Recent Insider Transactions • Feb 22
Insider recently bought ₹161k worth of stock On the 17th of February, Pragnya Donthineni bought around 303 shares on-market at roughly ₹530 per share. This trade did not impact their existing holding. In the last 3 months, there was an even bigger purchase from another insider worth ₹5.0m. Insiders have collectively bought ₹5.3m more in shares than they have sold in the last 12 months. Announcement • Feb 14
NATCO Pharma Limited Files Generic Olaparib Tablets in USA NATCO Pharma Limited announced submission of Abbreviated New Drug Application (ANDA) containing a paragraph IV certification with the U.S. Food and Drug Administration (FDA) for the generic version of Olaparib Tablets 100mg and 150mg. Olaparib is indicated primarily for certain forms of ovarian, breast, pancreatic and prostrate cancer. Olaparib Tablets are marketed in the United States (US) by AstraZeneca under brand Lynparza®. NATCO has been named as defendant in a lawsuit filed in the US district court of New Jersey by AstraZeneca and Kudos Pharmaceuticals. NATCO and its co-development and marketing partner Alembic Pharmaceuticals believe that the ANDA is possibly sole first-to-file based on its filing date and may be eligible for 180 days of marketing exclusivity at the time of launch of the product. Upcoming Dividend • Feb 14
Upcoming dividend of ₹1.25 per share at 1.2% yield Eligible shareholders must have bought the stock before 21 February 2023. Payment date: 01 March 2023. Payout ratio is a comfortable 26% and this is well supported by cash flows. Trailing yield: 1.2%. Lower than top quartile of Indian dividend payers (1.6%). Higher than average of industry peers (1.0%). Reported Earnings • Feb 10
Third quarter 2023 earnings: EPS and revenues miss analyst expectations Third quarter 2023 results: EPS: ₹3.41 (down from ₹4.41 in 3Q 2022). Revenue: ₹5.13b (down 8.4% from 3Q 2022). Net income: ₹623.0m (down 23% from 3Q 2022). Profit margin: 12% (down from 14% in 3Q 2022). The decrease in margin was driven by lower revenue. Revenue missed analyst estimates by 9.1%. Earnings per share (EPS) also missed analyst estimates by 13%. Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has fallen by 15% per year but the company’s share price has only fallen by 8% per year, which means it has not declined as severely as earnings. Announcement • Feb 10
NATCO Pharma Limited Approves Third Interim Dividend for the Financial Year 2022-23, Payable on March 1, 2023 NATCO Pharma Limited declared third interim dividend of INR 1.25 each per equity share of INR 2.00 each for the financial year 2022-23. The date for taking on record of its shareholders eligible for the purpose of payment of 3 Interim dividend i.e., record date is fixed as the February 21, 2023. The payment of said interim dividend will be from March 1, 2023. Announcement • Feb 01
NATCO Pharma Limited to Report Q3, 2023 Results on Feb 09, 2023 NATCO Pharma Limited announced that they will report Q3, 2023 results on Feb 09, 2023 Recent Insider Transactions • Dec 22
MD & Director recently bought ₹5.0m worth of stock On the 19th of December, Venkaiah Nannapaneni bought around 9k shares on-market at roughly ₹551 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought ₹5.1m more in shares than they have sold in the last 12 months. Announcement • Dec 07
Natco Pharma Limited Announces Double Bench of the High Court of Delhi Dismiss an Appeal Filed by FMC Corporation, FMC Singapore and FMC India Natco Pharma Limited announced that Double Bench of the Hon'ble High Court of Delhi has dismissed an appeal filed by FMC Corporation, FMC Singapore and FMC India and has upheld prima facie the Judgement of the Hon'ble Single Judge that the Natco Chlorantraniliprole (CTPR) Process does not infringe FMC's Indian Patent 298645. Price Target Changed • Nov 21
Price target decreased to ₹709 Down from ₹766, the current price target is an average from 12 analysts. New target price is 25% above last closing price of ₹569. Stock is down 29% over the past year. The company is forecast to post earnings per share of ₹46.34 for next year compared to ₹9.32 last year. Upcoming Dividend • Nov 16
Upcoming dividend of ₹0.75 per share Eligible shareholders must have bought the stock before 21 November 2022. Payment date: 10 December 2022. Payout ratio is a comfortable 28% and this is well supported by cash flows. Trailing yield: 1.1%. Lower than top quartile of Indian dividend payers (1.5%). Higher than average of industry peers (0.9%). Board Change • Nov 16
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 2 experienced directors. 7 highly experienced directors. Executive VP of Technical Operations & Director Pavan Bhat was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Nov 12
Second quarter 2023 earnings: EPS and revenues miss analyst expectations Second quarter 2023 results: EPS: ₹3.11 (down from ₹3.57 in 2Q 2022). Revenue: ₹4.32b (up 15% from 2Q 2022). Net income: ₹568.0m (down 13% from 2Q 2022). Profit margin: 13% (down from 17% in 2Q 2022). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 32%. Earnings per share (EPS) also missed analyst estimates by 39%. Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has fallen by 19% per year but the company’s share price has increased by 1% per year, which means it is well ahead of earnings. Announcement • Nov 10
NATCO Pharma Limited Declares Second Interim Dividend for the Financial Year 2022-23, Payable from 30 November 2022 NATCO Pharma Limited informed that the Board of Directors of the Company at their meeting held November 10, 2022 have considered and declared 2nd interim dividend of INR 0.75 (seventy-five paise only i.e., 37.5%) each per equity share of INR 2 (Rupees two only) each for the financial year 2022-23. The date for taking on record of its shareholders eligible for the purpose of payment of 2nd interim dividend i.e., record date is fixed as Tuesday the 22ndday of November 2022. The payment of said interim dividend will be paid from 30th November 2022. Announcement • Nov 02
NATCO Pharma Limited to Report Q2, 2023 Results on Nov 10, 2022 NATCO Pharma Limited announced that they will report Q2, 2023 results on Nov 10, 2022 Announcement • Oct 22
Natco Pharma Limited Announces FMC Corporation and FMC Singapore Serve A Copy of Appeal on Natco Natco Pharma Limited announced that FMC Corporation and FMC Singapore have served a copy of appeal on Natco. The Appeal is against the well-reasoned and clear judgement of the Hon'ble High Court of Delhi dated 19th September, 2022 which enabled Natco to launch its CTPR (Chlorantraniliprole) products. Natco is confident of its case and is confident of its success in the appeal. Announcement • Sep 24
Natco Pharma Limited Launches Chlorantraniliprole Natco Pharma Limited has launched Chlorantraniliprole (CTPR) 18.5% SC under the Brand Name of NATGEN in Indian Market. The company estimates the current market size of CTPR containing products in India to be over INR 20,000 million. Announcement • Sep 03
NATCO Pharma Limited, Annual General Meeting, Sep 30, 2022 NATCO Pharma Limited, Annual General Meeting, Sep 30, 2022, at 10:30 Indian Standard Time. Agenda: To consider and adopt audited Annual Financial Statements for the Financial Year 2021-22; to consider and confirm three interim dividends aggregating to Rs.4.50 per share paid on equity shares during the Financial Year 2021-22 as dividend for the FY 2021-22; to consider re-appointment of Dr. D. Linga Rao as a Director liable to retire by rotation; to consider ratification of remuneration of Cost Auditors; and to consider appointment of Dr. Pavan Ganapati Bhat as Director & Executive Vice President of the Company. Announcement • Aug 18
NATCO Announces Tentative Approval to Its ANDA for Trabectedin (Generic for Yondelis®) NATCO Pharma Limited announces that the U.S. Food and Drug Administration has granted tentative approval to its Abbreviated New Drug Application (ANDA) for Trabectedin for Injection (generic for Yondelis®) for the 1mg/vial presentation. Upcoming Dividend • Aug 12
Upcoming dividend of ₹3.50 per share Eligible shareholders must have bought the stock before 19 August 2022. Payment date: 30 August 2022. Trailing yield: 0.7%. Lower than top quartile of Indian dividend payers (1.7%). Lower than average of industry peers (1.0%). Reported Earnings • Aug 11
First quarter 2023 earnings: EPS and revenues exceed analyst expectations First quarter 2023 results: EPS: ₹17.55 (up from ₹4.11 in 1Q 2022). Revenue: ₹8.85b (up 116% from 1Q 2022). Net income: ₹3.20b (up 327% from 1Q 2022). Profit margin: 36% (up from 18% in 1Q 2022). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 8.4%. Earnings per share (EPS) also surpassed analyst estimates by 42%. Over the next year, revenue is forecast to grow 38%, compared to a 13% growth forecast for the industry in India. Over the last 3 years on average, earnings per share has fallen by 24% per year but the company’s share price has increased by 5% per year, which means it is well ahead of earnings. Announcement • Aug 10
NATCO Pharma Limited Declares Interim Dividend for the Financial Year 2022-23, Payable on August 30, 2022 NATCO Pharma Limited at its board of meeting held on August 9, 2022 declared interim dividend of INR 3.50 (Rupees Three Rupees fifty paise only) 175%) each per equity share of INR 2 (Rupees two only) each for the financial year 2022-23. The date for taking on record of its shareholders eligible for the purpose of payment of interim dividend i.e., record date is fixed as Monday the 22"d day of August, 2022 . The payment of said interim dividend will be paid from 30th August 2022. Announcement • Aug 03
NATCO Pharma Limited to Report Q1, 2023 Results on Aug 09, 2022 NATCO Pharma Limited announced that they will report Q1, 2023 results on Aug 09, 2022 Announcement • Jun 02
NATCO Pharma Limited Announces the Launch of the First Generic Version of Nexavar® (Sorafenib) Tablets in 200 Mg Strength in the U.S. Market NATCO Pharma Limited announced the launch of the first generic version of Nexavar® (Sorafenib) Tablets in 200 mg strength in the U.S. market. The product will be launched by NATCO's commercial partner Viatris, a global pharmaceutical company. Sorafenib is prescribed for treatment of unresectable Hepatocellular Carcinoma (HCC), advanced Renal Cell Carcinoma (RCC) and Differentiated Thyroid Carcinoma (DTC). 
